About The Summit

The Indian Pharma Market is estimated to be ~18.5 Bn USD and has the potential to grow to ~USD 80-90 Bn USD in the next 10 years

India is ranked as 10th in value and will soon be 4th, is ranked 3rd in Volume and will soon be 2nd.

Furthermore, the complications introduced by COVID-19 have had a big impact and ramifications on the overall biopharma industry.

As we are at such an important juncture of another pivotal shift in industry dynamics, it is time to look forward, review and analyze key drivers and trends that will lead India’s success and create exciting possibilities for the industry in the coming years.

Hear it from the leaders in the Indian BioPharma industry on the path forward for the sector in India.

  • The Indian Pharma Market is estimated to be ~18.5 Bn USD and has the potential to grow to ~USD 80-90 Bn USD in the next 10 years. India is ranked as 10th in value and will soon be 4th, is ranked 3rd in Volume and will soon be 2nd

  • Pharma, a well-established industry in India, combined with rising personal incomes and government healthcare outlays, is predicted to lead to annual average growth of around 16-17 per cent in the near future. Efforts to improve medical infrastructure, rising health pandemics, growing health insurance penetration and investments in research & development are amongst factors that will result in this growth.

  • Traditionally, the Indian pharmaceutical industry has focused primarily on generics as a business model, enjoying a leading position in the global generic pharmaceutical space, accounting for over 20% of global exports and nearly 80% of market share

Key Highlights

Thought leadership and Innovation is the need of the hour as the industry looks for the next big push.

New Chemical Entities (NCEs) take a long time to develop, often at a cost of over $1billion. Conversely, the development of a supergeneric is more comparable to that of a generic compound, as it has a known mechanism of action and an established safety and efficacy profile.

Biologics and Biosimilars is expected to be the next area for growth. The first Biosimilar in India was approved in 2000 and since then almost 100 biosimilars have been approved, majority of which have come in the last 5 years.

Now, it’s more important than ever, to have a crystal clear regulatory and reimbursement framework for these newer therapies.

As the industry is changing fast, we have to make sure that we are fleet-footed when it comes to adapting to technological advancements and manufacturing methods.

Newer tools in data sciences are paving way for faster processing of information resulting in increased ability to find hidden correlations and draw insights from the data.

The pharmaceutical industry has become one of India’s largest sectors, in terms of revenue as well as employment. As the country is moving towards making itself a global leader in end-to-end discovery and innovation, the talent landscape is also strengthening.

As the industry is changing fast, we have to make sure that we are fleet-footed when it comes to adapting to technological advancements and manufacturing methods.

  • WHO SHOULD ATTEND
  • WHO SHOULD SPONSOR

Pharma Business Leaders

Pharma and Biotech Research Leaders

Business Development and Sales Leaders

Pharma IT Leaders

Pharma HR Leaders

Regulatory and Govt. Affairs

CEOs

CSO/CBO/CSO/CXOs

Procurement Heads

Manufacturers

Service Providers

Supply Chain

Manufacturing

API Providers

Supply Chain

Medical Devices

Reagents and Scientific Supplies

Analytics and Consulting

Technology Companies

Sourcing

Recruitment

Partnering

Pharmacovigilance

Regulatory Affairs

Gold Partner

Industry Partner

Branding Partner

Digital Transformation Partner

Networking Partner

Bronze Partner

Investment Banking Partner

BIORx

Strategic Partner

Association Partner

Faba

Knowledge Partner

C-Camp

Express Pharma, today India’s leading business fortnightly for the pharmaceutical industry

Pharma Utility, a magazine dedicated to news and services in the Indian pharmaceutical industry.

India's most comprehensive online pharma news service. It provides updates on Indian pharma industry

IJDRA is Quarterly Open-access and peer-reviewed Journal circulated electronically and Print since 2013 .

Register Now

    For Sponsorship Opportunities :

    Register Now

      Delegates Fees

      Early Bird Fees 19,500/- + GST ( Valid till 16th April 2021)

      Standard Fees : Rs. 22,500/- + GST

      Register & Pay Now

      For Sponsorship Opportunities :

      Copyright @ 2020 bluetech-media.com, All Rights Reserved,
      Design & Develope by webtech.ooo